Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PureTech Health plc - American Depositary Shares (NQ:PRTC)

17.12 -0.93 (-5.18%)
Streaming Delayed Price Updated: 12:25 PM EDT, Apr 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PureTech Health plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
From PureTech
Via Business Wire
News headline image
PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
From PureTech Health plc
Via Business Wire
News headline image
Earnings Scheduled For April 30, 2025 ↗
 
Via Benzinga
News headline image
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces Annual Results for Year Ended December 31, 2024
From PureTech Health plc
Via Business Wire
News headline image
PureTech Health: Notice of Results
From PureTech Health plc
Via Business Wire
News headline image
PureTech Appoints Peel Hunt as Joint UK Corporate Broker
From PureTech Health plc
Via Business Wire
News headline image
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
PureTech Health plc Statement Regarding Press Speculation
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
From PureTech Health plc
Via Business Wire
News headline image
PureTech to Present at the Leerink Partners Global Healthcare Conference
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform
From PureTech Health plc
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
From PureTech Health plc
Via Business Wire
News headline image
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
From PureTech Health plc
Via Business Wire
News headline image
PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference
From PureTech Health plc
Via Business Wire
News headline image
PureTech Appoints UBS as UK Corporate Broker
From PureTech Health plc
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
PureTech's Lung Disease Candidate Slowed Lung Function Decline In Idiopathic Pulmonary Fibrosis Patients ↗
PureTech Health's Phase 2b trial of deupirfenidone for IPF met its primary endpoint, showing significant lung function improvement and dose-dependent benefits. 
Via Benzinga
News headline image
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
From PureTech Health plc
Via Business Wire
News headline image
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
From PureTech Health plc
Via Business Wire
News headline image
PureTech to Present at Two Upcoming Investor Conferences
From PureTech Health
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round
From PureTech Health plc
Via Business Wire
News headline image
PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting
From PureTech Health plc
Via Business Wire
News headline image
PureTech to Present at CHEST 2024 Annual Meeting
From PureTech Health
Via Business Wire
News headline image
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades ↗
Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors without... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.